pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
MIRUM · news · pharmadog
← back to MIRUM
News mentioning MIRUM
19
stories
8d
Mirum plans FDA submission for hepatitis D treatment as competition brews
endpoints
8d
Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run
fiercebiotech
9d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
9d
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
biospace
9d
Vir hepatitis D drug succeeds in first pivotal study
biopharma dive
10d
Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead
fiercebiotech
10d
Vir says hepatitis D drug combination succeeds in first pivotal study
endpoints
27d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
Oct 12, 26
Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
endpoints
Sep 30, 26
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
Sep 30, 26
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
Sep 28, 26
Mirum reports Phase 3 victory for acquired hepatitis D med
endpoints
Sep 28, 26
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
Sep 28, 26
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
fiercebiotech
Sep 25, 26
FDA approves Mirum’s drug for ultra-rare soft tissue disease
endpoints
Sep 24, 26
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Aug 20, 26
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
Jun 16, 26
Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pill
endpoints